| Literature DB >> 34763086 |
Shuyu Wang1, Fanrui Zeng2, Shumei Liang3, Qiuping Wang3, Yang Wen3, Qiongyao Wang4, Jiexia Zhang5, Man Li3, Shun Fang3, Ting Wei4, Minglun Li6, Farkhad Manapov6, Jian Zhang7, Linlang Guo8.
Abstract
This article has been withdrawn at the request of the editor-in-chief. Following publication of this article, the editor-in-chief discovered evidence of image duplication in Figures 1I, 1J, 3F, S5B, and S6B. Given the duplication of several western blots representing several gene products, the editor-in-chief has lost faith in the findings presented in this article. The authors maintain that these image duplications were the result of errors in file management and do not affect the conclusions of the study. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.Entities:
Keywords: Linc00173; YB1; glucose metabolism; in vitro; in vivo; long noncoding RNA; molecular mechanisms; multidrug resistance; small cell lung cancer; therapeutic targets; tissue samples
Year: 2021 PMID: 34763086 DOI: 10.1016/j.ymthe.2021.11.003
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 12.910